



Press Release

FOR IMMEDIATE RELEASE

Cellzome Acquires GlaxoSmithKline's Cell Map Unit

London, UK & HEIDELBERG, Germany, Sep 27, 2001

Cellzome GmbH and GlaxoSmithKline PLC (NYSE: GSK) today announced that Cellzome has acquired GSK's UK based unit Cell Map, which focuses on mapping protein-protein interactions in the cell to enable drug target discovery and validation. This alliance combines Cellzome's strength in large scale functional proteomics with the biological and pharmaceutical focus of Cell Map's team. Furthermore, it represents a major milestone in Cellzome's mission to develop mode of action-based drugs, and will support the company's efforts as it moves toward product development and commercialization. Under the terms of the agreement, GlaxoSmithKline will become a minority shareholder of Cellzome. Other financial terms of the agreement were not disclosed.

This acquisition represents an expansion of Cellzome's core capabilities. GSK's Cell Map team brings existing collaborations focused on important therapeutic areas, direct pharma R&D expertise, and access to complementary intellectual property and know-how. A number of GSK scientists will become Cellzome employees, establish operations in laboratory facilities just north of London and continue working with the Cell Map technology. GSK's desire to spin out this unit into a company focused on mapping cellular interactions implements GSK's strategy to maximize its R&D intellectual property assets externally through creative, innovative structures with appropriate third party partners.

"The Cell Map acquisition is part of Cellzome's effort to compress the time required to validate lead compounds and move toward the development of drugs of significant medical need and commercial potential," said Dr. Charles Cohen, Chief Executive Officer of Cellzome. "We will develop accurately targeted medicines from a deeper understanding of the context in which a target operates. This alliance will bring the scale necessary to reach the full potential of the technology".

"Combining the strengths and expertise of our two companies through this relationship will help speed the

For further information please contact:

GlaxoSmithKline PLC

Graeme P. Holland
Director, Science Communications
Tel: +44 (0) 1279 644369
Graeme.P.Holland@sbphrd.com

Cellzome AG

Charles Cohen, Ph.D., President and CEO
Tel: +49-62 21-137 57-0
charles.cohen@cellzome.com

Noonan Russo/Presence Euro RSCG

Lydia Sanmarti Vila, Ph.D. (USA)
Tel: +1-212-696 4455 ext.226
l.sanmarti@nrp-euro.com

drug discovery process by improving the selection and validation processes," said Allen Roses, MD, Senior Vice President, Genetics Research at GlaxoSmithKline. "Having this expertise will enable us to overcome a major bottleneck in the area of biological validation of targets. This is why GlaxoSmithKline incubated the Cell Map unit to map the cellular interactions for therapeutically important proteins. This deal typifies GSK's strategic vision of maximising the value of our investment in key technologies externally through creative, innovative structures."

Dr. Walter Blackstock, the director of the Cell Map unit, will join Cellzome as Vice President, Technology. "The Cell Map technology has demonstrated the ability to identify novel interaction partners for therapeutically important proteins," said Dr. Blackstock. "This information will play a decisive role in deepening our understanding of existing high-value drug targets."

Cellzome's newly acquired facilities will be located close to Mill Hill and the Medical Research Council (MRC). This north London location with excellent communication links will aid in recruitment and exposure to other researchers. Cellzome's headquarters will remain in Heidelberg, Germany on the EMBL campus.

About GSK

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Learn more at www.gsk.com

About Cellzome

Cellzome GmbH, based in Heidelberg, Germany, is a biopharmaceutical company that uses its proprietary functional proteomics technology for target discovery, validation, and drug development. The Company was founded in May 2000 with a team of scientists from the European Molecular Biology Laboratory (EMBL), including pioneers in the fields of protein mass spectrometry, bioinformatics, structural biology and signal transduction. Learn more at www.cellzome.com